A new drug for ALS: phase 1/2 safety and effectiveness trial
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new drug called TP04HN106 for people with ALS. It aims to see if it is safe and if it might slow down the disease. You may qualify if your breathing is still fairly good and you have been on a stable dose of riluzole.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of ALS by specific criteria.
- You must be at least 18 years old.
- Your breathing function must still be fairly good (score of at least 1 on the breathing questions of the ALSFRS-R scale).
- You must have been taking a stable dose of riluzole for at least 7 days before the trial and continue it.
- You must be willing to follow all study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial tests a new way of giving riluzole, a medicine already used for ALS, by delivering it directly into the fluid around the spinal cord using a small pump. It aims to see if this method is safe and might work better for people with ALS.
This study tests an experimental drug called PLL001 for people with ALS. It aims to see if the drug is safe and whether it can slow the progression of the disease.
This trial tests whether a medicine called cyclophosphamide can slow the progression of ALS. It's given to people who have had symptoms for less than 2 years and still have good breathing, to see if calming the immune system can help protect nerve cells.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.